Free Content Measuring visual field progression in the Early Manifest Glaucoma Trial

Authors: Heijl, Anders1; Leske, M. Cristina2; Bengtsson, Boel1; Bengtsson, Bo1; Hussein, Mohamed2

Source: Acta Ophthalmologica Scandinavica, Volume 81, Number 3, June 2003 , pp. 286-293(8)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

. Aims: 

The Early Manifest Glaucoma Trial (EMGT) (316 eligible eyes) has used a new set of criteria to define visual field progression in glaucoma. This paper provides estimates of the amount of visual field worsening required to reach the EMGT definition of definite perimetric progression. Methods: 

In the 148 eyes that reached definite progression, we first determined changes between baseline and the time of definite EMGT progression, both for mean deviation (MD) and for number of highly (p < 0.5%) significantly depressed test points in pattern deviation probability maps. Second, we studied whether such changes depended on baseline MD, intraocular pressure (IOP), age and time to progression, all of which are factors that affect the rate of field progression. Results: 

In eyes reaching progression, the mean change in MD from baseline was −1.93 dB (SE ± 0.20) and the mean change in number of significant points was +4.85 (SE ± 0.35). These changes did not show linear dependency on baseline MD, IOP or time to progression. Conclusions: 

The average amount of field deterioration needed to reach EMGT visual field progression has been measured and expressed in more conventional units (i.e. a loss of about − 2dB in MD and an increase in about five highly significant points). These estimates will facilitate the clinical interpretation of the results of EMGT.

Document Type: Research article

DOI: 10.1034/j.1600-0420.2003.00070.x

Affiliations: 1: Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden 2: Department of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, New York, USA

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A